WO1997025023A1 - Skin treatment formulation and uses thereof - Google Patents

Skin treatment formulation and uses thereof Download PDF

Info

Publication number
WO1997025023A1
WO1997025023A1 PCT/IT1997/000002 IT9700002W WO9725023A1 WO 1997025023 A1 WO1997025023 A1 WO 1997025023A1 IT 9700002 W IT9700002 W IT 9700002W WO 9725023 A1 WO9725023 A1 WO 9725023A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
hydrolysed
preparation according
equivalent
preparation
Prior art date
Application number
PCT/IT1997/000002
Other languages
English (en)
French (fr)
Inventor
Guido Paduano
Original Assignee
Guido Paduano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guido Paduano filed Critical Guido Paduano
Priority to BR9706943A priority Critical patent/BR9706943A/pt
Priority to EP97900732A priority patent/EP0873113A1/en
Priority to AU13185/97A priority patent/AU709842B2/en
Publication of WO1997025023A1 publication Critical patent/WO1997025023A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8164—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a compound for the treatment of skin pathologies and unaesthetic conditions and optionally of pathologies of the skin and related tissues. More particularly, the invention relates to a product for the treatment of: 1. skin atrophy striae, 2 skin wrinkles,
  • the invention also relates to the uses of the said compound.
  • Background art Skin atrophy and the phenomena associated therewith are mainly due to a deficiency in the two proteins of the skin, collagen and elastin, the first being responsible for nourishing and revitalizing the skin tissues while the second has the function of making the skin tissues elastic.
  • the subject of the present invention is a product for the treatment of skin pathologies and unaesthetic conditions and optionally of pathologies of the skin, based on elastin and collagen, which product makes it possible to obtain better and especially longer lasting results.
  • the product of the invention contains a combination of at least the following components: 1) collagen, 2) elastin,
  • a suitable vehicle which may also consist of a physiologically acceptable solution, depending on the type of administration for which the formulation is intended.
  • vascularization In certain cases, a reduction in vascularization accompanies the unaesthetic skin conditions mentioned.
  • administration of the optional local vasodilator together with the collagen and elastin makes it possible to re-establish peripheral blood circulation in the zone treated, thereby giving rise to localized vasodilation and thus allowing the two proteins to reach the treated zones.
  • the temporary vasodilation produced by the vasodilatory substance helps vascularization in the tissues and facilitates the provision of nutrients by the blood.
  • RNA helps the tissues receiving it to manufacture proteins with characteristics similar to the proteins administered, while RNA serves to create a memory, in the tissues receiving it, for the two proteins supplied in order to allow the tissues themselves to reproduce these proteins.
  • RNA or DNA therefore makes it possible to accelerate the healing process by stimulating the autonomous production of collagen and elastin by the skin tissues being treated.
  • the two acids are preferably used in combination, but appreciable results may also be obtained with only one of the two acids or the respective salt.
  • the compound may comprise, besides the four main components referred to above, one or more secondary components chosen from one or more of the following groups: amino acids; - enzymes and coenzymes; Vitamin C keratin (restricted to treatment of the scalp) .
  • useful enzymes for the use according to the invention are the following: pepsin, pyridoxine (Vitamin B6 coenzyme) , biotin or Vitamin H (Vitamin B6 coenzyme) .
  • pepsin pyridoxine
  • pyridoxine Vitamin B6 coenzyme
  • biotin or Vitamin H Vitamin H
  • the amino acids added to the formulation metabolize the proteins, that is to say they are involved in the formation of collagen and elastin.
  • the enzymes and coenzymes are catalysts of the process of protein metabolism, that is to say they increase the rate of biochemical reaction of the amino acids to proteins. Their presence in combination with amino acids therefore accelerates the metabolization of protein.
  • antioxidant represented by Vitamin C
  • Keratin the use of which is limited to formulations for treating the scalp, constitutes specific nourishment for promoting the regrowth and strengthening of the hair.
  • composition of the product varies depending on the mode of administration, in particular as regards the vehicles and the excipients.
  • the four fundamental components or five in the case of the use of both DNA and RNA
  • they may be used in the following amounts, expressed in parts by weight, including in the absence of other components: Hydrolysed collagen: 3-10 parts
  • RNA Sodium ribonucleate (RNA) 3-10 parts Excipients and vehicles qs
  • the sodium deoxyribonucleate and ribonucleate can be used independently of or in combination with each other.
  • compositions varying within the following ranges, again expressed in parts by weight:
  • RNA Sodium ribonucleate 4-8 parts in the presence of appropriate vehicles and/or excipients.
  • appropriate vehicles and/or excipients for administration by subcutaneous or intradermal injection or infiltration, the components mentioned above are prepared in a physiological solution, which in this case represents the vehicle. Typically, the parts by weight shown above are combined with 1000 parts by weight of physiological solution.
  • Appropriate excipients and vehicles are used for topical administration, and a few examples of these will be given in the following text together with respective amounts, with respect to a few particularly effective formulations.
  • secondary components such as certain enzymes and amino acids.
  • a formulation to which all the secondary components mentioned above have been added is given below.
  • the composition relates to an amount of 10 ml, equivalent to 10 g in physiological solution:
  • Vitamin C 350-650 mg Hydrolysed keratin (*) 20-40 mg
  • compositions given above remain valid for topical application as regards the first fifteen components, except that they would be in a different and— higher concentration, in view of the increased difficulty of absorption and the increased dispersion. Moreover, the physiological solution would be replaced by a combination of various vehicles and excipients.
  • compositions may be used, relative to 10 g of product (where the preferred amounts, again in mg, are shown in parentheses) :
  • Hydrolysed collagen 65-200 mg 90-170
  • Procaine hydrochloride 20-60 mg (30-50)
  • Vehicle hydrogenated polyoxyethylenated castor oil 100-300 mg (150-230)
  • ampules for topical use in the treatment of atrophy in which case the excipient is replaced by water, with the addition of preserving agents.
  • Ampules for the treatment of the scalp may have the same composition as ampules for the treatment of atrophy, with the addition of keratin in an amount of from 60 to 120 mg per 10 g of product.
  • the DNA and the RNA may also be used in the form of potassium deoxyribonucleate and potassium ribonucleate or in another compatible form.
  • the application methods vary depending on the type of treatment and on the route of administration. The latter may be carried out topically or by infiltration via subcutaneous, intra- or mesodermal injection of the compound into the site of the atrophies.
  • the number of applications and the amount of product applied vary according to the area of tissue to be treated and its condition. A few general indications are given below, which a person skilled in the art will use as a guideline for selecting the most suitable mode of application in each individual case.
  • Treatment of cutaneous striae subcutaneous infiltrations are performed, using a syringe with a microneedle, by inserting the needle parallel to the surface of the stria along its entire length.
  • a tunnel is formed which is filled with the solution as the needle is withdrawn.
  • intradermal infiltrations are performed, using a syringe with a microneedle, by inserting the needle parallel to the surface of the wrinkle along its entire length.
  • a tunnel is formed- which is filled with the solution as the needle is withdrawn.
  • mesodermal infiltrations that is to say infiltrations into the dermis but to a deeper level than intradermal infiltrations
  • a syringe with a microneedle in order to provide deep and diffuse nourishment for the tissues concerned.
  • Treatment of the scalp and of alopecia intradermal infiltrations into the scalp (trichomesotherapy) are performed using a syringe with a microneedle.
  • Treatment of skin chapping intradermal infiltrations are performed into the area concerned using a syringe with a microneedle. 6. Treatment of slow cicatrization: intradermal infiltrations are performed into the area concerned using a syringe with a microneedle.
  • the number of applications depends on the seriousness of the condition of the tissue treated. In general, the number of applications may range from 5 to 50.
  • the amount of solution administered varies according to the size of the area under treatment. Generally speaking, about 0.1 ml of product per cm 2 of tissue treated may be applied in the treatment of cutaneous striae.
  • Cosmetic treatment by means of topical application of the compound is carried out by rubbing the ampule preparation onto the area to be treated or by massaging into the area concerned in the case of cream preparations.
  • Topical use involves application twice daily over a period varying between one and six months, depending on the seriousness of the condition of the skin tissue.
  • NaCI queous solution (0.9%): stabilized pig-collagen 30 g/l sterilized pig-elastin 10/15 g/l glycine 2/4 g/l proline 6/10 g/l hydroxyproline 2/4 g/l
  • Collagen and elastin may be of animal or vegetal origin.
  • a process for obtaining hydrolysed cross ⁇ linked collagen and hydrolysed cross-linked elastin is described hereinbelow:
  • A.stabilised pig-collagen is mixed in a vacutainer under nitrogen atmosphere at 35/38° for 90 min.; B.the product is filtered on a 1-micrometre filter;
  • steps C, D and E are repeated;
  • gelatine On the bottom of the container a translucent homogeneous gelatine is collected.
  • the gelatine may be brought at the desired viscosity by addition of a sterilized 0.9% acqueous solution of NaCI.
  • Hydrolized aminoacids, hydrolized DNA and RNA and hydrolized biotin as well as procaine hydrocloride are added to the proteins treated as above described in order to obtain the above preparation.
  • the same process can be used with twice the amount of elastin and collagen (i.e. 60 g/l collagen and 20/30 g/l elastin.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/IT1997/000002 1996-01-10 1997-01-08 Skin treatment formulation and uses thereof WO1997025023A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR9706943A BR9706943A (pt) 1996-01-10 1997-01-08 Formulação de tratamento de pele e seus usos
EP97900732A EP0873113A1 (en) 1996-01-10 1997-01-08 Skin treatment formulation and uses thereof
AU13185/97A AU709842B2 (en) 1996-01-10 1997-01-08 Skin treatment formulation and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI96A000002 1996-01-10
IT96FI000002A IT1289845B1 (it) 1996-01-10 1996-01-10 Formula per il trattamento della cute e suoi impieghi

Publications (1)

Publication Number Publication Date
WO1997025023A1 true WO1997025023A1 (en) 1997-07-17

Family

ID=11351445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1997/000002 WO1997025023A1 (en) 1996-01-10 1997-01-08 Skin treatment formulation and uses thereof

Country Status (6)

Country Link
EP (1) EP0873113A1 (enrdf_load_stackoverflow)
AU (1) AU709842B2 (enrdf_load_stackoverflow)
BR (1) BR9706943A (enrdf_load_stackoverflow)
CA (1) CA2242636A1 (enrdf_load_stackoverflow)
IT (1) IT1289845B1 (enrdf_load_stackoverflow)
WO (1) WO1997025023A1 (enrdf_load_stackoverflow)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031337A1 (fr) * 1997-01-21 1998-07-23 Thorel Jean Noel Produits cosmetiques ou dermo-pharmaceutiques respectant l'ecologie cutanee
WO2003045340A1 (en) * 2001-11-27 2003-06-05 Unilever Plc Hair treatment compositions
WO2003082230A3 (en) * 2002-03-28 2003-11-27 Procter & Gamble Topical use of vitamin b6 compositions
ITRM20090124A1 (it) * 2009-03-23 2010-09-23 Marco Nicoletti Composizione cosmetica contenente collagene ed elastina
WO2012101473A1 (en) * 2011-01-27 2012-08-02 Abdula Kurkayev Nanocomposite formulations and method of skin care treatment for rejuvanation and correction of skin defects
JP2013221005A (ja) * 2012-04-16 2013-10-28 Katsumi Yamaguchi 肌質改善組成物及びその製造方法
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
US12285487B2 (en) 2012-12-31 2025-04-29 Jrx Biotechnology, Inc. Liquid topical pharmaceutical nano-emulsion formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE726015A (enrdf_load_stackoverflow) * 1966-06-20 1969-05-29
FR2592790A1 (fr) * 1986-01-16 1987-07-17 Villano Guy Preparation cosmetique a action regeneratrice et antirides
FR2609393A1 (fr) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques comprenant une substance azotee, notamment aminoacides, oligo- ou polypeptides, proteines, et leurs derives, et composition pharmaceutique ou cosmetique ainsi preparee.
EP0283893A1 (en) * 1987-03-23 1988-09-28 R.P. DENIS S.p.A. Novel cosmetic formulations
EP0471135A2 (en) * 1990-08-14 1992-02-19 Kenneth M. Hallam Compositions, medicaments and methods for the promotion of hair growth
JPH06128138A (ja) * 1992-10-15 1994-05-10 Kyowa Hakko Kogyo Co Ltd 化粧料

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE726015A (enrdf_load_stackoverflow) * 1966-06-20 1969-05-29
FR2592790A1 (fr) * 1986-01-16 1987-07-17 Villano Guy Preparation cosmetique a action regeneratrice et antirides
EP0283893A1 (en) * 1987-03-23 1988-09-28 R.P. DENIS S.p.A. Novel cosmetic formulations
FR2609393A1 (fr) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques comprenant une substance azotee, notamment aminoacides, oligo- ou polypeptides, proteines, et leurs derives, et composition pharmaceutique ou cosmetique ainsi preparee.
EP0471135A2 (en) * 1990-08-14 1992-02-19 Kenneth M. Hallam Compositions, medicaments and methods for the promotion of hair growth
JPH06128138A (ja) * 1992-10-15 1994-05-10 Kyowa Hakko Kogyo Co Ltd 化粧料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 121, no. 8, 22 August 1994, Columbus, Ohio, US; abstract no. 91353, SUZUKI, TADASHI ET AL: "cosmetics for rough skin" XP002030251 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031337A1 (fr) * 1997-01-21 1998-07-23 Thorel Jean Noel Produits cosmetiques ou dermo-pharmaceutiques respectant l'ecologie cutanee
US6342236B1 (en) 1997-01-21 2002-01-29 THOREL JEAN-NOëL Cosmetic products compatible with cutaneous ecology
WO2003045340A1 (en) * 2001-11-27 2003-06-05 Unilever Plc Hair treatment compositions
WO2003082230A3 (en) * 2002-03-28 2003-11-27 Procter & Gamble Topical use of vitamin b6 compositions
US7235249B2 (en) 2002-03-28 2007-06-26 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions
ITRM20090124A1 (it) * 2009-03-23 2010-09-23 Marco Nicoletti Composizione cosmetica contenente collagene ed elastina
WO2012101473A1 (en) * 2011-01-27 2012-08-02 Abdula Kurkayev Nanocomposite formulations and method of skin care treatment for rejuvanation and correction of skin defects
JP2013221005A (ja) * 2012-04-16 2013-10-28 Katsumi Yamaguchi 肌質改善組成物及びその製造方法
US12285487B2 (en) 2012-12-31 2025-04-29 Jrx Biotechnology, Inc. Liquid topical pharmaceutical nano-emulsion formulations
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization

Also Published As

Publication number Publication date
BR9706943A (pt) 1999-04-06
EP0873113A1 (en) 1998-10-28
AU709842B2 (en) 1999-09-09
CA2242636A1 (en) 1997-07-17
ITFI960002A1 (it) 1997-07-10
AU1318597A (en) 1997-08-01
ITFI960002A0 (enrdf_load_stackoverflow) 1996-01-10
IT1289845B1 (it) 1998-10-16

Similar Documents

Publication Publication Date Title
AU611915B2 (en) Method for inducing biological coverings in wounds
US6270811B1 (en) Pharmaceutical, cosmetic composition with base of microbial culture mixed with an essential oil and an acid
US8603973B2 (en) Skincare composition comprising HSA fusion protein, preparation method and uses thereof
KR20120089433A (ko) 충전제와 섬유아세포 성장 배지를 조합한 주사용 조성물
CA2042014A1 (en) Method of treating or preventing baldness with compositions containing fibroblast growth factor
CN101453985A (zh) 促进毛发生长的组合物
JPS63185918A (ja) 化粧用組成物
ZA200606515B (en) Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds
JP3321712B2 (ja) マツエキス含有外用養毛剤
AU709842B2 (en) Skin treatment formulation and uses thereof
US6858201B2 (en) Methods for treating fingernails and toenails
RU2202362C2 (ru) Композиция для местного применения, содержащая фактор роста эпидермиса человека
US20200164037A1 (en) Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth
GB2210789A (en) Topical application for skin care
CN101596310A (zh) 一种用于创面修复的人工基底膜乳膏
JPS617209A (ja) 育毛剤組成物
RU2292906C2 (ru) Фармацевтические и косметические композиции, содержащие плацентарный фактор роста plgf-1
US20050276766A1 (en) Methods and compositions for increasing skin remodeling
US20040234476A1 (en) Cosmetic preparation with anti-wrinkle action
CA2525670A1 (en) Hair regenerator
CH713030B1 (de) Dermokosmetische Zusammensetzung, die plättchenähnliche Synthesemoleküle zur Behandlung der Hautalterung und zur Stimulierung des Haarwuchses enthält.
JPH01305010A (ja) 化粧料
HK1078469B (en) Pharmaceutical and cosmetic compositions comprising plgf-1
HK1036221B (en) Topical composition containing human epidermal growth factor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2242636

Country of ref document: CA

Ref country code: CA

Ref document number: 2242636

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997900732

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997900732

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97525062

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1997900732

Country of ref document: EP